The endometrium: Pathologic principles and pitfalls

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 3, 2007, Pages 372-382

  Silverberg, Steven G ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INVASION; CANCER STAGING; CURETTAGE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; OVARY CARCINOMA; REVIEW; ADENOCARCINOMA; BIOPSY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; FEMALE; METHODOLOGY; MYOMETRIUM; PATHOLOGY;

ADENOCARCINOMA; BIOPSY; CARCINOMA, ENDOMETRIOID; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYSTERECTOMY; MYOMETRIUM; PATHOLOGY, CLINICAL;

EID: 33847734723     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Buckley CH, Fox H. Biopsy Pathology of the Endometrium. London, England: Arnold; 2002.
2. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: a eview of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2002;9:145-184.
3. Crum CP, Hornstein MD, Nucci MR, et al. Hertig and beyond: a systematic and practical approach to the endometrial biopsy. Adv Anat Pathol. 2003;10:301-318.
4. Ioffe OB. Recent developments and selected diagnostic problems in carcinomas of the endometrium. Am J Clin Pathol. 2005;124(suppl 1):S42-S51.
5. Mazur MT. Endometrial hyperplasia/adenocarcinoma: a conventional approach. Ann Diagn Pathol. 2005;9:174-181.
6. Mazur MT, Kurman RJ. Diagnosis of Endometrial Biopsies and Curettings: A Practical Approach. 2nd ed. New York, NY: Springer Science+Business Media; 2005.
7. Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol. 2000;13:309-327.
8. Silverberg SC, Tabbara SO. The uterine corpus. In: Silverberg SC, DeLellis RA, Frable WJ, LiVolsi VA, Wick MR, eds. Silverberg's Principles and Practice of Surgical Pathology and Cytopathohgy. 4th ed. Philadelphia, Pa: Churchill Livingstone; 2006:1933-1986.
9. Silverberg SC, Kurman RJ, Nogales F, et al. Tumours of the uterine corpus: epithelial tumours and related lesions. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:221-232. World Health Organization Classification of Tumours.
10. Zaino RJ. Interpretation of Endometrial Biopsies and Curettings. 2nd ed. Philadelphia, Pa: Lippincott-Raven; 1996.
11. Silverberg SG, for the members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with carcinomas of the endometrium: a basis for checklists. Arch Pathol Lab Med. 1999;123:28-32.
12. Association of Directors of Anatomic and Surgical Pathology. ADASP checklists and guidelines for surgical pathology reports of malignant neoplasms. Checklist version 1.1. 2003. Available at: http://www.adasp.org/Checklists/ checklists.htm.
13. Schenker JG, Margalioth EJ. Intrauterine adhesions: an updated appraisal. Fertig Steril. 1982;37:593-610.
14. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260-1267.
15. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol. 1995;19:417-432.
16. Soslow RA, Pirog E, Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol. 2000;24:726-732.
17. Hill CB, Prihoda TJ, Sharkey FE. Number of levels needed for diagnosis of endometrial biopsies. Histopathology. 2005;47:225-226.
18. Torpin R, Pund E, Peebles WJ. The aetiologic pathologic factors in a series of 1741 fibromyomas of the uterus. Am J Obstet Gynecol. 1992;44:569-574.
19. Vollenhoven B, Lawrence A, Healy D. Uterine fibroids: a clinical review. Br J Obstet Gynaecol. 1990;97:285-298.
20. Wilkinson N, Rollason TP. Recent advances in the pathology of smooth muscle tumours of the uterus. Histopathology. 2001;39:331-341.
21. Goldblum JR, Clement PB, Hart WR. Adenomyosis with sparse glands: a potential mimic of low-grade endometrial stromal sarcoma. Am J Clin Pathol. 1995;103:218-223.
22. Shutter J, Wright TC. Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol. 2005;24:313-318.
23. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group Study. Cancer. 2006;106:812-819.
24. Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group Study. Cancer. 2006;106:804-811.
25. Kaku T, Tsuruchi N, Tsukamoto N, et al. Reassessment of myometrial invasion in endometrial carcinoma. Obstet Gynecol. 1994;84:979-982.
26. Sidawy MK, Silverberg SG. Endometrial carcinoma: pathologic factors of therapeutic and prognostic significance. Patbol Ann. 1992;27:153-186.
27. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55-65.
28. Zaino RJ. Conventional and novel prognostic factors in endometrioid adenocarcinoma: a critical appraisal. Pathol Case Rev. 2000;5:138-152.
29. Atad J, Weill S, Ben-David Y, et al. Intraoperative frozen section examination of myometrial invasion depth in patients with endometrial carcinoma. Int J Gynecol Cancer. 1994;4:352-355.
30. Franchi M, Ghezzi F, Melpignano M, et al. Clinical value of intraoperative gross examination in endometrial cancer. Gynecol Oncol. 2000;76:357-361.
31. Vorgias G, Hintipas E, Katsoulis M, etal. Intraoperative gross examination of myometrial invasion and cervical infiltration in patients with endometrial cancer: decision-making accuracy. Gynecol Oncol. 2002;85:483-486.
32. Jacques SM, Qureshi F, Munkarah A, Lawrence WD. Interinstitutional surgical pathology review in gynecologic oncology, II: endometrial cancer in hysterectomy specimens. Int J Gynecol Pathol. 1998;17:42-45.
33. Mittal KR, Barwick KW. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis. Gynecol Oncol. 1993;49:197-201.
34. Koshiyama M, Suzuki A, Ozawa M, et al. Adenocarcinomas arising from uterine adenomyosis: a report of four cases. Int J Gynecol Pathol. 2002;21:239-245.
35. Longacre TA, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am J Surg Pathol. 1999;23:69-78.
36. Mittal KR, Barwick KW. Diffusely infiltrating adenocarcinoma of the endometrium: a subtype with poor prognosis. Am J Surg Pathol. 1988;12:754-758.
37. Lee KR, Vacek PM, Belinson JL. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol Oncol. 1994;54:10-18.
38. Landry D, Mai KT, Senterman MK, et al. Endometrioid adenocarcinoma of the uterus with a minimal deviation invasive pattern. Histopathology. 2003;42:77-82.
39. Ambros RA, Kurman RJ. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer. 1992;69:1424-1431.
40. Mariani A, Webb MJ, Keeney GL, et al. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002;84:437-442.
41. Yamazawa K, Seki K, Matsui H, et al. Significance of perivascular lymphocytic infiltrates in endometrial carcinoma. Cancer. 2001;91:1777-1784.
42. Scott M, Lyness RW, McCluggage WG. Atypical reactive proliferation of endocervix: a common lesion associated with endometrial carcinoma and likely related to prior endometrial sampling. Mod Pathol 2006;19:470-474.
43. Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas: a prospective clinicopathologic study of 74 cases: a Gynecologic Oncology Group study. Gynecol Oncol. 2001;83:355-362.
44. Irving JA, Catasús L, Gallardo A, et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the β-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol. 2005;36:605-619.
45. Robboy SJ, Datto MB. Synchronous endometrial and ovarian tumors: metastatic disease or independent primaries? Hum Pathol. 2005;36:597-599.
46. Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004;94:456-462.
47. Fadare O, Mariappan MR, Hileeto D, et al. Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer. Mod Pathol. 2005;18:673-680.
48. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
49. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260-1267.
50. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-1578.
51. Halperin R, Zehavi S, Habler L, et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol. 2001;22:122-126.
52. Zaino RJ, Kurman RJ, Brunetto VL, et al. Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a Gynecologic On-cology Group study. Am J Surg Pathol. 1998;22:1379-1385.
53. Esteller M, Garcia A, Martinez-Palones JM, et al. Clinicopathologic features and genetic alterations in endometrioid carcinoma of the uterus with villoglandular differentiation. Am J Clin Pathol. 1999;111:336-342.
54. Boruta DM II, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer. 2004;101:2214-2221.
55. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797-806.
56. Hui P, Kelly M, O'Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol. 2005;18:75-82.
57. Kurman RJ, Kaminski PF, Nords HJ. The behavior of endometrial hyperplasia: a long-term study of 'untreated' hyperplasia in 170 patients. Cancer. 1985;56:403-412.
58. Winkler B, Alvarez S, Richart RM, et al. Pitfalls in the diagnosis of endometrial neoplasia. Obstet Gynecol. 1984;64:185-194.
59. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 1998;22:1012-1019.
60. Bergeron C, Nogales FF, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with the proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol. 1999;23:1102-1108.
61. Hecht JL, Ince TA, Baak JPA, et al. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol. 2005;18:324-330.